接受来那度胺发热反应的复发多发性骨髓瘤患者的细胞因子谱 - Suppr

Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.

作者信息

Morita Yasuyoshi, Shimada Takahiro, Yamaguchi Terufumi, Rai Shinya, Hirase Chikara, Emoto Masakatsu, Serizawa Kentaro, Taniguchi Yasuhiro, Ojima Mayuko, Tatsumi Yoichi, Ashida Takashi, Matsumura Itaru

出版信息

Int J Hematol. 2011 Dec;94(6):583-4. doi: 10.1007/s12185-011-0973-x. Epub 2011 Nov 30.

DOI:10.1007/s12185-011-0973-x

PMID:22127558

Abstract

摘要

相似文献

Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.

Int J Hematol. 2011 Dec;94(6):583-4. doi: 10.1007/s12185-011-0973-x. Epub 2011 Nov 30.

Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.

Leuk Lymphoma. 2014 Jul;55(7):1691-3. doi: 10.3109/10428194.2013.853300. Epub 2014 Jan 28.

Desensitization to lenalidomide in a patient with relapsed multiple myeloma.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):162-5. doi: 10.1016/j.clml.2012.09.003. Epub 2012 Oct 26.

Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.

Leuk Lymphoma. 2013 Dec;54(12):2753-5. doi: 10.3109/10428194.2013.786072.

Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma.

Int J Hematol. 2011 Feb;93(2):257-259. doi: 10.1007/s12185-011-0775-1. Epub 2011 Feb 1.

Diffuse alveolar hemorrhage associated with lenalidomide.

Int J Hematol. 2011 Jun;93(6):830-831. doi: 10.1007/s12185-011-0871-2. Epub 2011 May 15.

Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.

Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):191-6. doi: 10.1016/j.clml.2012.01.001. Epub 2012 Feb 16.

[The use of lenalidomide in the treatment of multiple myeloma].

Klin Onkol. 2010;23(2):67-72.

Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma.

Eur J Clin Pharmacol. 2012 May;68(5):881-4. doi: 10.1007/s00228-011-1152-y. Epub 2011 Nov 30.

Lenalidomide and its role in the management of multiple myeloma.

Expert Rev Anticancer Ther. 2008 Jun;8(6):865-74. doi: 10.1586/14737140.8.6.865.

引用本文的文献

Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.

Int J Hematol. 2013 Jun;97(6):743-8. doi: 10.1007/s12185-013-1321-0. Epub 2013 Apr 23.

本文引用的文献

Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma.

Int J Hematol. 2011 Feb;93(2):257-259. doi: 10.1007/s12185-011-0775-1. Epub 2011 Feb 1.

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Leukemia. 2010 Jan;24(1):22-32. doi: 10.1038/leu.2009.236. Epub 2009 Nov 12.

Immunomodulatory drugs in multiple myeloma.

Expert Opin Investig Drugs. 2005 Nov;14(11):1411-8. doi: 10.1517/13543784.14.11.1411.

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.

Br J Cancer. 2002 Nov 4;87(10):1166-72. doi: 10.1038/sj.bjc.6600607.

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Blood. 2002 Nov 1;100(9):3063-7. doi: 10.1182/blood-2002-03-0996.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.

作者信息

出版信息

Int J Hematol. 2011 Dec;94(6):583-4. doi: 10.1007/s12185-011-0973-x. Epub 2011 Nov 30.

DOI:10.1007/s12185-011-0973-x

PMID:22127558

Abstract

摘要

相似文献

Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.

Int J Hematol. 2011 Dec;94(6):583-4. doi: 10.1007/s12185-011-0973-x. Epub 2011 Nov 30.

Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.

Leuk Lymphoma. 2014 Jul;55(7):1691-3. doi: 10.3109/10428194.2013.853300. Epub 2014 Jan 28.

Desensitization to lenalidomide in a patient with relapsed multiple myeloma.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):162-5. doi: 10.1016/j.clml.2012.09.003. Epub 2012 Oct 26.

Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.

Leuk Lymphoma. 2013 Dec;54(12):2753-5. doi: 10.3109/10428194.2013.786072.

Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma.

Int J Hematol. 2011 Feb;93(2):257-259. doi: 10.1007/s12185-011-0775-1. Epub 2011 Feb 1.

Diffuse alveolar hemorrhage associated with lenalidomide.

Int J Hematol. 2011 Jun;93(6):830-831. doi: 10.1007/s12185-011-0871-2. Epub 2011 May 15.

Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.

Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):191-6. doi: 10.1016/j.clml.2012.01.001. Epub 2012 Feb 16.

[The use of lenalidomide in the treatment of multiple myeloma].

Klin Onkol. 2010;23(2):67-72.

Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma.

Eur J Clin Pharmacol. 2012 May;68(5):881-4. doi: 10.1007/s00228-011-1152-y. Epub 2011 Nov 30.

Lenalidomide and its role in the management of multiple myeloma.

Expert Rev Anticancer Ther. 2008 Jun;8(6):865-74. doi: 10.1586/14737140.8.6.865.

引用本文的文献

Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.

Int J Hematol. 2013 Jun;97(6):743-8. doi: 10.1007/s12185-013-1321-0. Epub 2013 Apr 23.

本文引用的文献

Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma.

Int J Hematol. 2011 Feb;93(2):257-259. doi: 10.1007/s12185-011-0775-1. Epub 2011 Feb 1.

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Leukemia. 2010 Jan;24(1):22-32. doi: 10.1038/leu.2009.236. Epub 2009 Nov 12.

Immunomodulatory drugs in multiple myeloma.

Expert Opin Investig Drugs. 2005 Nov;14(11):1411-8. doi: 10.1517/13543784.14.11.1411.

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.

Br J Cancer. 2002 Nov 4;87(10):1166-72. doi: 10.1038/sj.bjc.6600607.

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Blood. 2002 Nov 1;100(9):3063-7. doi: 10.1182/blood-2002-03-0996.

Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献